Quotient Limited (NASDAQ:QTNT) insider D J. Paul E. Cowan sold 30,197 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $4.92, for a total value of $148,569.24. Following the sale, the insider now owns 26,666 shares of the company’s stock, valued at $131,196.72. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Quotient Limited (NASDAQ QTNT) traded up 2.16% during midday trading on Friday, hitting $5.21. The stock had a trading volume of 350,324 shares. The stock has a 50-day moving average price of $4.66 and a 200 day moving average price of $5.86. The firm’s market cap is $74.90 million. Quotient Limited has a 12-month low of $3.22 and a 12-month high of $7.74.
Quotient Limited (NASDAQ:QTNT) last released its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, meeting the consensus estimate of ($0.55). Quotient Limited had a negative net margin of 381.66% and a negative return on equity of 13,050.41%. The business had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million. On average, equities analysts anticipate that Quotient Limited will post ($2.01) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/27/quotient-limited-qtnt-insider-d-j-paul-e-cowan-sells-30197-shares.html.
A number of equities research analysts have recently issued reports on QTNT shares. Zacks Investment Research upgraded Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, September 20th. BTIG Research restated a “buy” rating and issued a $12.00 price target on shares of Quotient Limited in a research report on Thursday, August 31st. Finally, ValuEngine upgraded Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th.
Several large investors have recently modified their holdings of QTNT. FNY Partners Fund LP purchased a new stake in shares of Quotient Limited in the 1st quarter valued at approximately $636,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Quotient Limited in the 2nd quarter valued at approximately $341,000. Rhumbline Advisers purchased a new stake in shares of Quotient Limited in the 2nd quarter valued at approximately $201,000. Bank of New York Mellon Corp purchased a new stake in shares of Quotient Limited in the 2nd quarter valued at approximately $451,000. Finally, Birchview Capital LP lifted its position in shares of Quotient Limited by 36.9% in the 2nd quarter. Birchview Capital LP now owns 79,700 shares of the company’s stock valued at $587,000 after acquiring an additional 21,500 shares in the last quarter. Institutional investors and hedge funds own 57.70% of the company’s stock.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.